Rockwell Medical is a fully integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency anemia, secondary hyperparathyroidism and hemodialysis throughout the U.S. and abroad. Learn more
Bio-Pharma Development Program
The company’s lead bio-pharmaceutical iron drug Triferic was commercially launched in the U.S. September 2015 and is designed to prevent and treat iron deficiency anemia in end-stage renal disease patients. As part of the our long-term growth strategy, the company is establishing global partnerships and licensing opportunities for world-wide distribution and sale of all it's therapies.
Diseases of the kidney are a major health concern in the United States, affecting more than 30 million Americans and causing more than 100,000 deaths annually. Learn more